Koh HK, Geller AC, VanderWeele TJ. Deaths of COVID-19. Jama. 2021; 325: 133–4.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurological manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77: 683–90.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397: 220–32.
Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, et al. Comparison of serum neurodegenerative biosigns among hospitalized patients COVID-19 versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer’s dementia. Alzheimer’s Dementia: J Alzheimer’s Assoc. 2022; 18: 899–910.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric findings in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021; 8: 416–27.
Marshall M. How COVID-19 can damage the brain. Nature. 2020; 585: 342–3.
Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Mechanisms of entry of SARS-CoV-2 cells. Proc Natl Acad Sci United States. 2020; 117: 11727–34.
Farhadian SF, Seilhean D, Spudich S. Neuropathogenesis of acute coronavirus disease 2019. Curr Opin Neurol. 2021; 34: 417–22.
Zhang BZ, Chu H, Han S, Shuai H, Deng J, Hu YF, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020; 30: 928–31.
Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021; 218: e20202135.
Zang X, Chen S, Zhu J, Ma J, Zhai Y. The emerging role of central and peripheral immune systems in neurodegenerative diseases. Front Aging Neurosci. 2022; 14: 872134.
Fani Maleki A, Rivest S. Native immune cells: Monocytes, monocyte-derived macrophages, and microglia as therapeutic targets for Alzheimer’s disease and multiple sclerosis. Anterior Cell Neurosis. 2019; 13: 355.
Greenhalgh AD, David S, Bennett FC. Immune cell regulation of glia during CNS injury and disease. Nat Rev Neurosci. 2020; 21: 139–52.
Liu QQ, Cheng A, Wang Y, Li H, Hu L, Zhao X, et al. Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study. BMJ Open. 2020; 10: e041471.
Kempuraj D, Thangavel R, Selvakumar GP, Zaheer S, Ahmed ME, Raikwar SP, et al. Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration. Anterior Cell Neurosis. 2017; 11: 216.
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140: 918–34.
McCoy MK, Tansey MG. TNF signal inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008; 5:45.
Pratt J, Lester E, Parker R. Could SARS-CoV-2 cause taopathy? Lancet Neurol. 2021; 20: 506.
Pan P, Shen M, Yu Z, Ge W, Chen K, Tian M, et al. SARS-CoV-2 N protein promotes NLRP3 inflammatory activation to stimulate hyperinflammation. Nat Commun. 2021; 12: 4664.
Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammatory masses are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021; 218: e20201707.
Tahira AC, Verjovski-Almeida S, Ferreira ST. Dementia is an age-independent risk factor for severity and death in patients with COVID-19. Alzheimer’s Dementia: J Alzheimer’s Assoc. 2021; 17: 1818–1831.
Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM, et al. Effects of COVID-19 on the clinical features of Parkinson’s disease: a community-based case-control study. Mov Disord: Off J Mov Disord Soc. 2020; 35: 1287–92.
Brundin P, Nath A, Beckham JD. Is COVID-19 a perfect storm for Parkinson’s disease? Trends Neurosci. 2020; 43: 931–3.
Lee S, Arcila-London X, Steijlen K, Newman D, Grover K. Case report of ALS patient with COVID-19 infection (5032). Neurology. 2021; 96 15 Suppl: 5032.
Google Scholar
Matias-Guiu JA, Delgado-Alonso C, Yus M, Polidura C, Gómez-Ruiz N, Valles-Salgado M, et al. “Brain Mist” from COVID-19 or Alzheimer’s disease? Case report. Front Psychol. 2021; 12: 724022.
The COVID-19 Host Genetics Initiative, a global initiative to explain the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Homa Gen: EJHG. 2020; 28: 715–8.
Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019; 51: 404–13.
Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of new risk sites, causal insights, and hereditary risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019; 18: 1091–102.
Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide analyzes identify KIF5A as a novel ALS gene. Neuron. 2018; 97: 1268–1283.e1266.
International Multiple Sclerosis Genetic Consortium. A multiple sclerosis genome map involves peripheral immune cells and microglia in susceptibility. Science. 2019; 365: eaav7188.
Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014; 13: 686–99.
Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, et al. Genome sequence analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021; 53: 294–303.
Lu Q, Li B, Ou D, Erlendsdottir M, Powles RL, Jiang T, et al. A powerful approach to estimating annotation-layered genetic covariance by GWAS summary statistics. Am J Hum Genet. 2017; 101: 939–64.
Bowden J, Davey, Smith G, Haycock PC, Burgess S. Consistent assessment in Mendelian randomization with a number of invalid instruments using a weighted environmental estimator. Genet Epidemiol. 2016; 40: 304–14.
Verbanck M, Chen CY, Neale B, Do R. Detection of generalized horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex features and diseases. Nat Genet. 2018; 50: 693–8.
Burgess S, Thompson SG. Interpreting results of mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017; 32: 377–89.
Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-test Mendelian randomization. Genet Epidemiol. 2016; 40: 597–608.
Brion MJ, Shakhbazov K, Visscher PM. Calculation of statistical power in Mendelian randomization studies. Int J Epidemiol. 2013; 42: 1497–501.
Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR Base platform supports systematic causal inference across the human phenomenon. eLife. 2018; 7: e34408.
Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with a comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7: 611–27.
Miners S, Kehoe PG, Love S. Cognitive effect of COVID-19: Looking beyond the short term. Alzheimer’s Res Ther. 2020; 12: 170.
Zhou H, Lu S, Chen J, Wei N, Wang D, Lyu H, et al. The landscape of cognitive function in cured patients with COVID-19. J Psychiatrist Res. 2020; 129: 98–102.
Park HY, Song IA, Oh TK. Risk of dementia among coronavirus disease survivors: A nationwide cohort study in South Korea. J Personalized Med. 2021; 11: 1015.
of Erausquin GA, Snyder H, Carrillo M, Hosseini AA, Brugha TS, Seshadri S. The chronic neuropsychiatric consequences of COVID-19: The need for a possible study of viral effect on brain functioning. Alzheimer’s Dement: J Alzheimer’s Assoc. 2021; 17: 1056–65.
Google Scholar
Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer’s-like signaling in brains of COVID-19 patients. Alzheimer’s Dementia: J Alzheimer’s Assoc. 2022; 18: 955–965.
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer’s Res Ther. 2020; 12:69.
Zhou Y, Xu J, Hou Y, Leverenz JB, Kallianpur A, Mehra R, et al. Online medicine links SARS-CoV-2 / COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimer’s Res Ther. 2021; 13: 110.
#COVID19 #risk #neurodegenerative #disorders #Mendelian #randomized #study #Translation #Psychiatry